Mark Vignola | Intercept Pharmaceuticals, Inc. |
Mark Pruzanski | Intercept Pharmaceuticals, Inc. |
Richard Kim | Intercept Pharmaceuticals, Inc. |
Lisa Bright | Intercept Pharmaceuticals, Inc. |
Sandip S. Kapadia | Intercept Pharmaceuticals, Inc. |
Brian Abrahams | RBC Capital Markets LLC |
Jay Olson | Oppenheimer & Co., Inc. |
Alan Carr | Needham & Co. LLC |
Kevin Patel | Goldman Sachs & Co. LLC |
Kelechi Chikere | Jefferies LLC |
Joel L. Beatty | Citigroup Global Markets, Inc. |
Nick Abbott | Wells Fargo Securities LLC |
Irina Margine | Cowen & Co. LLC |
Ying Huang | Bank of America Merrill Lynch |
Thank you for joining the Intercept Pharmaceuticals First Quarter 2018 Financial Results Conference Call. All participants are now in a listen-only mode.
Following opening remarks, Intercept's management will open the lines for a question-and-answer period. Please be advised that this call is being recorded at the company's request and a webcast of this call will be archived on the company's website for two weeks from today's date. I would now like to introduce Dr.